Singh Sourabh, Soni Deepti, Sahoo Anjan Kumar, Mukhopadhyay Sramana
Department of Pathology and Lab Medicine, AIIMS, Bhopal 462020, Madhya Pradesh, India.
Department of Otorhinolaryngology (ENT)- Head & Neck Surgery, AIIMS, Bhopal 462020, Madhya Pradesh, India.
Int J Surg Case Rep. 2024 Sep;122:110021. doi: 10.1016/j.ijscr.2024.110021. Epub 2024 Jul 15.
SMARCB1 (INI-1) is a vital tumour suppressor gene on chromosome 22q11.2, preventing tumour development in the SWI/SNF complex. Mutations cause SMARCB1-deficient tumours with distinct features. Loss of INI-1 expression is seen in malignancies, including sinonasal carcinoma and atypical teratoid/rhabdoid tumours. Recently recognized as a separate entity, SMARCB1-deficient sinonasal carcinomas (SDSC) are rare, clinically aggressive, and mimic other malignancies, emphasizing their significant diagnosis due to poorer prognosis, particularly in the elderly.
A 66-year-old male presented with a 4-month-old right cheek swelling, diagnosed initially as a sinonasal neoplastic mass. The biopsy revealed sinonasal mucosal fragments infiltrated by a tumour with plasmacytoid morphology. Immunohistochemistry (IHC) of the tumour cells was positive for p63 and pan-cytokeratin and showed INI-1 loss. Subsequent subtotal maxillectomy was performed, and the patient received adjuvant chemotherapy and radiotherapy. At a thirteen-month follow-up, the patient achieved his daily activities with no signs of recurrence.
The loss of protein expression in sinonasal cancer is predominantly attributed to the homozygous deletion of SMARCB1. SDSC, a profoundly invasive malignant carcinoma, tends to infiltrate sinuses and extend into the intracranial regions. The IHC findings of our case were in coherence with previous studies in SMARCB1. The prognosis is particularly unfavourable in males and advanced tumours.
The tumour's microscopic and immunohistochemical characteristics indicated the SDSC. Due to its aggressive nature and high mortality rates, dealing with a paranasal mass, one should be suspicious of this tumour.
SMARCB1(INI-1)是位于22q11.2染色体上的一个重要肿瘤抑制基因,可防止肿瘤在SWI/SNF复合物中发展。突变会导致具有独特特征的SMARCB1缺陷型肿瘤。INI-1表达缺失见于多种恶性肿瘤,包括鼻窦癌和非典型畸胎样/横纹肌样肿瘤。SMARCB1缺陷型鼻窦癌(SDSC)最近被确认为一个独立的实体,较为罕见,具有临床侵袭性,且与其他恶性肿瘤相似,因其预后较差,尤其是在老年人中,故强调其诊断的重要性。
一名66岁男性,右侧脸颊肿胀4个月,最初诊断为鼻窦肿瘤性肿块。活检显示鼻窦黏膜碎片被具有浆细胞样形态的肿瘤浸润。肿瘤细胞的免疫组织化学(IHC)检测显示p63和全细胞角蛋白呈阳性,且INI-1缺失。随后进行了次全上颌骨切除术,患者接受了辅助化疗和放疗。在13个月的随访中,患者能够进行日常活动,无复发迹象。
鼻窦癌中蛋白质表达缺失主要归因于SMARCB1的纯合缺失。SDSC是一种具有高度侵袭性的恶性癌,倾向于浸润鼻窦并延伸至颅内区域。我们病例的免疫组织化学结果与之前关于SMARCB1的研究一致。男性和晚期肿瘤的预后尤其不佳。
肿瘤的微观和免疫组织化学特征表明为SDSC。由于其侵袭性本质和高死亡率,处理鼻窦肿块时,应怀疑这种肿瘤。